Combine Conference (8, Jan. 07’ ) Case report Case report Reporter :NS R2 洪培恩 Reporter :NS R2 洪培恩 R3 吳孟庭 R3 吳孟庭.

Slides:



Advertisements
Similar presentations
TA OGUNLESI (FWACP)1 CHILDHOOD LEUKAEMIA. TA OGUNLESI (FWACP)2 LEUKAEMIA Heterogenous group of malignant disorders Characterised by uncontrolled clonal.
Advertisements

Combine conference R3 陳斯逸 /VS 孫銘希 Jan General data ID: F Male 67 y/o Farmer.
Show and Tell FIRM B - RED. Our team Dr. Clarke & Dr. Vargas Shinoj & Arvind Jacob & Muneeza Chloe, Lauren & Njiye.
HAEMATOLOGY MODULE: LYMPHOMA Adult Medical-Surgical Nursing.
Investigations of lymphoma
LYMPHOMAS By DR : Ramy A. Samy.
Proposed WHO Classification of Lymphoid neoplasm
Hodgkin Disease Definition: neoplastic disorder with development of specific infiltrate containing pathologic Reed-Sternberg cells. It usually arises in.
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Chronic lymphocytic leukemia (1)
Lymphoma Nada Mohamed Ahmed , MD, MT (ASCP)i.
Chapter 17 Chronic Leukemias.
Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.
Chronic Leukemia Dr. Rania Alhady Chronic Lymphocytic leukemia (CLL):
Non-Hodgkin’s lymphomas-definition and epidemiology
Eleni Galani Medical Oncologist
Enisa Zaric, MD Montenegro Specialist
NYU Medicine Grand Rounds Clinical Vignette Maryann Kwa, MD PGY-2 January 12, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Combine meeting 報告者 : NS R3 吳孟庭 醫師. Case 姓名 : 廖 xx 年齡 : 16 y/o Admission date: 性別 : 男 ID: I.
O THER MALIGNANT LYMPHOPROLIFERATIVE DISORDERS The lymphomas and plasma cell problems.
Treatment Evaluation of HTLV infection treatment of asymptomatic HTLV carriers is not indicated.
Edward Camacho Mina 1061 MD4 WINDSOR UNIVERSITY HODGKIN LYMPHOMA.
Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.
SYB Case 2 By: Amy. History 63 y/o female History of left breast infiltrating duct carcinoma s/p mastectomy in 1996 and chemotherapy ER negative, PR negative,
Metastatic Cancer – Gross Pathology Lymph node - metastasis from breastLiver – metastasis from lung Vertebral column – metastasis from prostate Mesentery.
Tumor markers Present; by Dr. Andalib Isfahan Medical School
Case discussion. Vs 李宜中,R1 林玫瑩. General data: Name: 賴錦 x Age:52 years old Occupation: 鐵工廠老闆 Admission date:2006/5/30.
NTUH Neurosurgery Morning Meeting Case Discussion Date: 2015/04/21 Presented by PGY 何御彰.
NYU Medical Grand Rounds Clinical Vignette Lisa Cioce MD, PGY-2 March 10, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Brain Biopsy Frozen Section/Touch Prep. Brain Biopsy for Suspected Neoplasm Is it Abnormal? Is it Neoplastic? What Type of Neoplasm is it? What is the.
Combine conference NS 張維傑 / Chief CC Shen.
Plasma cell Disorders S. Sami Kartı, MD, Prof.. Plasma cells  Terminally differentiated cells of B- lymphocyte lineage  Produce antibodies  Normal.
Multiple Myeloma Definition:
Malignancies of lymphoid cells ↑ incidence in general …. CLL is the most common form leukemia in US: Incidence in 2007: 15,340 Origin of Hodgkin lymphoma.
1 By Dr. Zahoor. Question 1 A 36 year old male patient presents with tiredness, headaches and following is the blood count:  Hb 9.2 g/dl  MCV 109 fl.
Case Study 42 Henry Armah, M.D., M.Phil.. Question 1 Clinical history: 80-year-old male with past medical history of malignant non-Hodgkin’s lymphoma,
Hematology and Hematologic Malignancies
Chronic leukemia 1. Chronic Lymphocytic leukemia (CLL) * Definition: Chronic neoplastic disorder characterized by accumulation of small mature-looking.
APPROACH TO LYMPHOID MALIGNANCIES. Patient Evaluation of ALL Careful history and PE CBC Chemistry studies Bone marrow biopsy Lumbar puncture.
MLAB Hematology Keri Brophy-Martinez Lymphoid Malignancies.
Pathology of the Urogenital Tract Male Genital Tract March 24, 2014.
HODGKIN’S LYMPHOMA. Anemia,bleeding tendency. Hepatosplenomegaly.
Future Directions in ALK Negative Anaplastic Large Cell Lymphoma
MLAB Hematology Keri Brophy-Martinez
Case Report Shao-Ching Chao, Chiung-Chyi Shen, Department of Neurosurgery Taichung Veterans General Hospital.
HEMATOPATHOLOGY MODULE Prepared by Emmanuel R. de la Fuente, M.D.
Clayton Wiley MD/PhD. 38-year-old male with progressive weakness of upper and lower extremities, in addition to confusion. Describe the MRI findings (location,
Acute lymphoblastic leukemia in children
Asymptomatic lymphadenopathy Mediastinal mass Systemic symptoms Fever, Pruritus Other nonspecific symptoms and paraneoplastic syndromes Intra-abdominal.
Non-Hodgkin Lymphoma March 13, 2013 Suzanne R. Fanning, DO Greenville Health System.
Clinical case Daniel Martinez Hernandez Hospital Clínic, Barcelona.
NON-HODGKIN’S LYMPHOMA
Leukemia An estimate reveals over 327,520 people in the U.S. are living with Leukemia. In India leukemia is ranked among the list of top cancers affecting.
By Dr. Zahoor DATA INTERPRETATION-2.
CASE OF THE MONTH Dr Narender Tejwani Consultant ( Hematopathologist)
By Dr. Zahoor DATA INTERPRETATION-2.
By Dr. Zahoor DATA INTERPRETATION-2.
Metastatic Breast cancer
AFP > 9000 without demonstrable HCC
A young patient with multiple myeloma
LEUKEMIA CASE STUDY 2.
Metastatic epithelioid angiosarcoma with bone marrow involvement
Diagnostic Hematology
Leukemia An estimate reveals over 327,520 people in the U.S. are living with Leukemia. In India leukemia is ranked among the list of top cancers affecting.
POEM Group Online Case Discussion Date: April 1, 2014
Case Study 35 Henry Armah, M.D., M.Phil..
Reporter: R4 何承宇 Supervisor : VS 林虞軒
Lymphomas.
General strategies of Cancer Treatment and evaluation of Response
Presentation transcript:

Combine Conference (8, Jan. 07’ ) Case report Case report Reporter :NS R2 洪培恩 Reporter :NS R2 洪培恩 R3 吳孟庭 R3 吳孟庭

Case 1 方 X, 68 Y/O, male 方 X, 68 Y/O, male ID: H ID: H Admission date: 95/12/12 ~ Admission date: 95/12/12 ~ Chief complaint: Progressive weakness of R't side limbs and dizziness with falling down accident for 5 days Chief complaint: Progressive weakness of R't side limbs and dizziness with falling down accident for 5 days

History 1. Personal Hx: Smoking 1PPD for 30 years Past Hx: Hypertension for 10+ years Past Hx: Hypertension for 10+ years 2. He was brought to 台大雲林分院 and brain MRI on 95/12/11 revealed L't parietal and frontal tumor lesion, suspected metastatic tumor. 3. Visit our NS OPD, Cons’ alert, MP:R‘t side limbs,Gr 2 4. Admission for further evaluation and treatment

Neurologic Examination Consciousness: E4V5M6 Consciousness: E4V5M6 Pupil: R/L: 3.0/3.0 without light reflex Pupil: R/L: 3.0/3.0 without light reflex Babinski sign: bilateral no response Babinski sign: bilateral no response No R-L disorientation, no dysphagia No R-L disorientation, no dysphagia Increased DTR, MP- RUE/RLE:Gr 2/2 Increased DTR, MP- RUE/RLE:Gr 2/2 CN: intact CN: intact Sensory function: intact Sensory function: intact

DateNa (mEq/l)K (mEq/l)Cre (mg/dl)Ca(mg/dl) DateWBC (/cumm) Hb (g/dl) Platelet (/cumm) Neu (%) Lym (%) K Tumor markers AFP 1.32 ng/ml CA Unit/ml CEA 2.78 ng/ml SCC < 0.3 ng/ml Free-PSA 0.57 ng/ml LaboratoryData

Image study CxR: Slight prominent bil. hilar regions CxR: Slight prominent bil. hilar regions Sono,Abdomen: non-significant finding Sono,Abdomen: non-significant finding Chest CT(contrast) on 12/14: Chest CT(contrast) on 12/14: Bullous formation in left upper lung, small subpleural infiltration in both lowers Bullous formation in left upper lung, small subpleural infiltration in both lowers Small lymphadenopathy in subaortic region of Small lymphadenopathy in subaortic region of mediastinum mediastinum

Operation (mass effect and for diagnosis) 2006/12/18 Left F-T-P craniotomy with removal of tumor under Brainlab navigator 2006/12/18 Left F-T-P craniotomy with removal of tumor under Brainlab navigator OP finding OP finding Gray brown soft tissue mass was found about 3 and 5 cm in size over left frontal and parietal region, respectively Gray brown soft tissue mass was found about 3 and 5 cm in size over left frontal and parietal region, respectively Froxen section: high grade malignancy Froxen section: high grade malignancy

Post op course Seizure episode x 1 (Depakene level: 39.9 ug/ml) Seizure episode x 1 (Depakene level: 39.9 ug/ml) Biopsy report: Peripheral T-cell lymphoma, unspecified. Biopsy report: Peripheral T-cell lymphoma, unspecified. Consult CCRT  WBRT(2000cGy/8fr.) start on 12/27 Consult CCRT  WBRT(2000cGy/8fr.) start on 12/27 For complete lymphoma staging  For complete lymphoma staging  CT,abdomen: No abnormal LAPs in the abdomen CT,abdomen: No abnormal LAPs in the abdomen Gallium scan: Increased uptake in the bil. pul. Hili Gallium scan: Increased uptake in the bil. pul. Hili Bone marrow examination: not representative, No lymphoma is seen Bone marrow examination: not representative, No lymphoma is seen

Further treatment Rehabilitation Rehabilitation Suggest chemoport placement and systemic chemotherapy Suggest chemoport placement and systemic chemotherapy

Final diagnosis Peripheral T-cell lymphoma with CNS metastasis Peripheral T-cell lymphoma with CNS metastasis

Peripheral T Cell Lymphoma They represent 7% of all cases of non-Hodgkin's lymphoma. They represent 7% of all cases of non-Hodgkin's lymphoma. T-cell prolymphocytic leukemia  a high white blood cell count, usually characteristic prolymphocytic morphology, and expression of surface CD3 with either CD4 or CD4 and CD8 T-cell prolymphocytic leukemia  a high white blood cell count, usually characteristic prolymphocytic morphology, and expression of surface CD3 with either CD4 or CD4 and CD8 T-cell large granular lymphocytic leukemia  most often CD3, CD8, CD57, and TIA-1 expression. T-cell large granular lymphocytic leukemia  most often CD3, CD8, CD57, and TIA-1 expression. aggressive NK-cell leukemias, and aggressive NK-cell leukemias, and adult T-cell lymphoma/leukemia.. adult T-cell lymphoma/leukemia..

Clinical Characteristics Median Age, years : 61 y/o Median Age, years : 61 y/o B Symptoms, % : 50% B Symptoms, % : 50% Bone Marrow Involvement, % : 36% Bone Marrow Involvement, % : 36% Gastrointestinal Tract Involvement, % : 15% Gastrointestinal Tract Involvement, % : 15% % Surviving 5 years : 25% % Surviving 5 years : 25%

Diagnosis Mostly CD4+, but a few will be CD8+, both CD4+ and CD8+, or have an NK cell immunophenotype. Mostly CD4+, but a few will be CD8+, both CD4+ and CD8+, or have an NK cell immunophenotype. No characteristic genetic abnormalities have yet been identified, but translocations involving the T cell antigen receptor genes on chromosomes 7 or 14 may be detected. No characteristic genetic abnormalities have yet been identified, but translocations involving the T cell antigen receptor genes on chromosomes 7 or 14 may be detected. human T-cell lymphoma/leukemia viruses I and II (HTLV-I and HTLV-II), Epstein-Barr virus (EBV), and human herpesvirus 8 (HHV- 8) sequences as previously described. human T-cell lymphoma/leukemia viruses I and II (HTLV-I and HTLV-II), Epstein-Barr virus (EBV), and human herpesvirus 8 (HHV- 8) sequences as previously described. The neoplastic nature of a T-cell infiltrate is established by histologic features in combination with failure to determine an inflammatory cause and demonstration of monoclonality of T-cell receptor genes. The neoplastic nature of a T-cell infiltrate is established by histologic features in combination with failure to determine an inflammatory cause and demonstration of monoclonality of T-cell receptor genes.

Immunohistochemistry Indirect biotin-avidin method --detect the antigens. Indirect biotin-avidin method --detect the antigens. Monoclonal antibodies used in the tests were for detecting CD20, CD30, and anaplastic lymphoma kinase (ALK) ; CD3, CD4, CD8, CD56, CD57, Ki-67, granzyme B, pancytokeratin, and glial fibrillary acidic protein and TiA-1. Monoclonal antibodies used in the tests were for detecting CD20, CD30, and anaplastic lymphoma kinase (ALK) ; CD3, CD4, CD8, CD56, CD57, Ki-67, granzyme B, pancytokeratin, and glial fibrillary acidic protein and TiA-1.

Stage evaluation of patient Physical examination Physical examination Documentation of B symptoms Documentation of B symptoms Laboratory evaluation Laboratory evaluation Complete blood counts Complete blood counts Liver function tests Liver function tests Uric acid Uric acid Chest radiograph Chest radiograph Calcium Calcium Serum protein electrophoresis Serum protein electrophoresis Serum B 2 -microglobulin Serum B 2 -microglobulin CT scan of abdomen, pelvis, and usually chest CT scan of abdomen, pelvis, and usually chest Bone marrow biopsy Bone marrow biopsy Lumbar puncture in lymphoblastic, Burkitt's, and diffuse large B cell lymphoma with positive marrow biopsy Lumbar puncture in lymphoblastic, Burkitt's, and diffuse large B cell lymphoma with positive marrow biopsy Gallium scan (SPECT) or PET scan in large-cell lymphoma Gallium scan (SPECT) or PET scan in large-cell lymphoma

Treatment Treatment regimens are the same as those used for diffuse large B cell lymphoma, but patients with peripheral T cell lymphoma have a poorer response to treatment. Treatment regimens are the same as those used for diffuse large B cell lymphoma, but patients with peripheral T cell lymphoma have a poorer response to treatment.

Thank you for attention